ReviewFrontiers in pharmacology2026
Mechanisms, prevention, and management of aminoglycoside-induced hearing loss in neonates and children: a translational review.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Aminoglycoside antibiotics remain essential for treating serious neonatal and pediatric infections, yet carry a well-documented risk of permanent auditory and vestibular toxicity. This review examines the pharmacological mechanisms of ototoxicity in pediatric populations, identifies those at highest risk, and assesses current prevention, monitoring, and management strategies. Methods: PubMed, EMBASE, Cochrane Library, Web of Science, and CINAHL were searched for relevant literature from 2000 to 2025. The primary focus was pediatric populations, though mechanistic and translational pharmacology work from other age groups was included. Results: The ototoxicity pathway is increasingly well characterized: aminoglycosides accumulate in cochlear hair cells via mechanoelectrical transduction channels, disrupt mitochondrial function, trigger oxidative stress, and cause cell death through apoptotic, necroptotic, and ferroptotic mechanisms. Susceptibility varies substantially. Patients carrying the MT-RNR1 m.1555A>G pharmacogenomic variant face a markedly elevated risk of profound hearing loss even with a single standard course. Preterm neonates are at higher risk than older children owing to renal immaturity, altered volume of distribution, and incomplete blood-labyrinth barrier development. Co-administration of loop diuretics and vancomycin further amplifies ototoxic risk. Extended-interval dosing is associated with equivalent efficacy and reduced nephrotoxicity, with a non-significant trend toward lower ototoxicity in pooled analyses. Point-of-care genetic screening allows identification of high-risk patients before the first dose, though debate continues over universal versus targeted implementation. Model-informed dosing approaches, including Bayesian forecasting and AUC-targeted monitoring, offer individualized pharmacokinetic optimization but remain underutilized. Antimicrobial stewardship and minimizing concomitant ototoxin exposure are complementary strategies. When ototoxicity occurs, early audiological and vestibular identification enables timely intervention through hearing aid fitting, cochlear implantation, vestibular rehabilitation, and family-centered support, though vestibular ototoxicity remains widely under-recognized in pediatric populations. Conclusion: Evidence-based interventions to reduce aminoglycoside ototoxicity in children exist, including pharmacogenomic screening and dosing optimization, as well as structured monitoring and rehabilitation. However, a persistent gap remains between available evidence and routine clinical implementation. Key research priorities include pediatric otoprotective trials, validated cochlear injury biomarkers, and implementation strategies for diverse healthcare settings. Given the permanence of aminoglycoside-induced ototoxic injury and its downstream effects on speech, language, and developmental outcomes, closing this gap represents an urgent clinical priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.